Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Charged multivesicular body protein 2A (CHMP2A) is a core component of the ESCRT-III complex, a multiprotein machinery that enables the formation and maturation of multivesicular bodies (MVBs)—endosomal compartments critical for degrading membrane proteins, sorting cellular cargo, and facilitating receptor downregulation[1][5]. CHMP2A specifically is required for membrane fission processes such as phagophore closure during autophagy, cytokinesis, and nuclear envelope reformation[1][2]. It plays a significant role in regulating autophagic flux and is fundamental to proper lysosomal turnover, with depletion leading to the accumulation of immature autophagosomal structures[2]. Additional evidence links CHMP2A with HIV-1 virus budding, cancer (as a breast adenocarcinoma marker), and neurodegenerative disease. It is regarded as a relevant molecular target for investigating vesicular trafficking, autophagy, and cellular homeostasis[1][2][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Charged multivesicular body protein 2A (CHMP2A).